STOCK TITAN

Nantahala Capital Files Schedule 13G/A Disclosing 7.96% of Bioventus

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Nantahala Capital Management, LLC and two principals report beneficial ownership of 5,280,842 shares of Bioventus Inc. Class A common stock, representing 7.96% of the outstanding class as of June 30, 2025. The filing states the shares are held by funds and separately managed accounts under Nantahala's control and that Nantahala and its managing members, Wilmot B. Harkey and Daniel Mack, share voting and dispositive power over these shares but have no sole voting or dispositive power. The filing is submitted on a Schedule 13G/A indicating the holdings are in the ordinary course of business and not intended to influence control of the issuer. The document includes the issuer address and signatures dated August 14, 2025.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Nantahala holds a near-8% passive stake (5.28M shares) in Bioventus, significant ownership but reported as passive under Schedule 13G/A.

Nantahala's 7.96% position is large enough to attract investor attention because it exceeds the 5% disclosure threshold and could influence liquidity or perception of investor support. However, the use of Schedule 13G/A and the certification that holdings are in the ordinary course suggests no active intent to change control. The shared voting/dispositive power indicates coordinated control across the adviser and its principals rather than individual sole control, which limits immediate governance implications. Monitor for any future amendments or Schedule 13D filings that would signal activist intentions.

TL;DR: A 7.96% shared position is material for governance monitoring but is presented as passive; no immediate governance action signaled.

The filing identifies Wilmot Harkey and Daniel Mack as managing members who may be deemed beneficial owners through their roles at Nantahala. The absence of sole voting power and the Schedule 13G/A classification reduce immediate governance concerns. Still, investors and the board should note the size of the stake because coordinated voting by a nearly 8% holder can affect close shareholder votes or proxy contests if positions change. The signatures and dates confirm the filing's timeliness and formal certification of passive intent.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Nantahala Capital Management, LLC
Signature:/s/ Taki Vasilakis
Name/Title:Taki Vasilakis / Chief Compliance Officer
Date:08/14/2025
Wilmot B. Harkey
Signature:/s/ Wilmot B. Harkey
Name/Title:Wilmot B. Harkey
Date:08/14/2025
Daniel Mack
Signature:/s/ Daniel Mack
Name/Title:Daniel Mack
Date:08/14/2025
Bioventus Inc.

NASDAQ:BVS

BVS Rankings

BVS Latest News

BVS Latest SEC Filings

BVS Stock Data

494.29M
59.07M
11.77%
73.52%
2.75%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
DURHAM